Amphastar Pharmaceuticals Inc (AMPH)
45.46
+0.91
(+2.04%)
USD |
NASDAQ |
Nov 22, 16:00
45.43
-0.03
(-0.07%)
After-Hours: 20:00
Amphastar Pharmaceuticals Revenue (Quarterly): 191.21M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 191.21M |
| June 30, 2024 | 182.39M |
| March 31, 2024 | 171.84M |
| December 31, 2023 | 178.10M |
| September 30, 2023 | 180.56M |
| June 30, 2023 | 145.71M |
| March 31, 2023 | 140.02M |
| December 31, 2022 | 135.02M |
| September 30, 2022 | 120.13M |
| June 30, 2022 | 123.47M |
| March 31, 2022 | 120.37M |
| December 31, 2021 | 120.89M |
| September 30, 2021 | 112.20M |
| June 30, 2021 | 101.66M |
| March 31, 2021 | 103.02M |
| December 31, 2020 | 95.92M |
| September 30, 2020 | 83.43M |
| June 30, 2020 | 85.81M |
| March 31, 2020 | 84.69M |
| December 31, 2019 | 83.38M |
| September 30, 2019 | 80.14M |
| June 30, 2019 | 79.05M |
| March 31, 2019 | 79.79M |
| December 31, 2018 | 89.69M |
| Date | Value |
|---|---|
| September 30, 2018 | 75.54M |
| June 30, 2018 | 71.04M |
| March 31, 2018 | 58.39M |
| December 31, 2017 | 60.40M |
| September 30, 2017 | 57.92M |
| June 30, 2017 | 65.19M |
| March 31, 2017 | 56.67M |
| December 31, 2016 | 63.54M |
| September 30, 2016 | 64.22M |
| June 30, 2016 | 68.03M |
| March 31, 2016 | 59.37M |
| December 31, 2015 | 76.91M |
| September 30, 2015 | 63.87M |
| June 30, 2015 | 53.85M |
| March 31, 2015 | 56.89M |
| December 31, 2014 | 55.88M |
| September 30, 2014 | 59.71M |
| June 30, 2014 | 49.00M |
| March 31, 2014 | 45.87M |
| December 31, 2013 | 54.88M |
| September 30, 2013 | 59.32M |
| June 30, 2013 | 62.52M |
| March 31, 2013 | 52.96M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
83.38M
Minimum
Dec 2019
191.21M
Maximum
Sep 2024
127.99M
Average
120.63M
Median
Revenue (Quarterly) Benchmarks
| Eli Lilly and Co | 11.44B |
| BridgeBio Pharma Inc | 2.732M |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 40.43M |
| Total Expenses (Quarterly) | 134.17M |
| EPS Diluted (Quarterly) | 0.78 |
| Enterprise Value | 2.532B |
| Gross Profit Margin (Quarterly) | 53.31% |
| Profit Margin (Quarterly) | 21.14% |
| Earnings Yield | 6.60% |
| Operating Earnings Yield | 8.98% |
| Normalized Earnings Yield | 6.599 |